Single Genome-Editing Strategy Can Help Treat Multiple Disorders
Table of Contents
Relevance:
Facts for Prelims – Genome editing technologies – Types of genetic mutations, GS Paper III – Science & Technology, Advances in genetic engineering, Precision medicine and rare disease treatment
For Prelims:
- Nonsense mutation, Premature stop codon (TAG), Genome editing, Prime editing, pegRNA (Prime-editing guide RNA), tRNA (Transfer RNA), PERT (Prime-Editing-mediated Readthrough of Premature Termination codons)
For Mains:
- Mutation-class therapy vs disease-specific therapy, Precision medicine approach, Repurposing cellular machinery for treatment, Efficiency comparison of genome-editing methods, Safety considerations in genome editing
Why in News?
A study published in Nature reports a single genome-editing strategy capable of treating multiple genetic diseases caused by nonsense mutations. Researchers from the Broad Institute, Harvard University, and the University of Minnesota developed a method using prime editing to restore protein production across different disorders.
Background: Genetic Disorders and Nonsense Mutations
- Genetic disorders often arise from small DNA sequence errors.
- Many diseases such as cystic fibrosis, Batten disease, and Tay-Sachs disease occur due to faulty protein production.
- A common error is the nonsense mutation:
- A single incorrect DNA change introduces a premature stop signal (stop codon).
- Protein synthesis stops early.
- Leads to incomplete or non-functional proteins.
- Nonsense mutations account for about one-quarter (25%) of disease-causing genetic changes.
Current Problem
- Each mutation halts protein formation at a different point.
- Therefore, separate therapies must be designed and approved individually.
- This makes treatment development slow, complex, and expensive.
Key Breakthrough
Instead of correcting each mutation separately, researchers developed a strategy called:
PERT – Prime-Editing-Mediated Readthrough of Premature Termination Codons
- Converts a cell’s own gene machinery into a tool that overrides faulty stop signals.
- Enables cells to ignore incorrect instructions and complete protein production.
Understanding Protein Production (Biological Basis)
- DNA is transcribed into messenger RNA (mRNA).
- mRNA contains three-letter genetic codes called codons.
- Transfer RNA (tRNA) reads codons and delivers matching amino acids.
- Ribosomes join amino acids to form proteins.
- Human cells contain hundreds of tRNA genes, many redundant.
- Altering some tRNAs is generally harmless, making them suitable therapeutic targets.
Repurposing tRNA Genes
Researchers used genome editing to modify tRNAs so they:
- Recognize premature stop signals.
- Insert amino acids instead of stopping translation.
- Allow full-length protein production.
Earlier attempts used natural suppressor tRNAs but faced issues:
- Safety concerns
- Poor durability
- Insufficient efficiency
Prime Editing Approach
- Uses a specialised molecule called prime-editing guide RNA (pegRNA).
- Guides editing machinery to a precise DNA location.
- Inserts required genetic templates without cutting DNA aggressively.
Key Achievement
- Demonstrated that a human tRNA gene can be rewritten to produce suppressor tRNA at safe natural levels.
- Edited cells bypassed premature stop codons while maintaining normal protein production.
Finding Effective Candidates
- Human cells contain 418 tRNA genes.
- Researchers screened them to identify suitable candidates.
- Four tRNAs — for:
- leucine
- arginine
- tyrosine
- serine
showed promise in suppressing the common stop codon TAG.
Optimization
- Thousands of engineered variants were created by:
- Adjusting DNA sequences
- Making structural modifications
- Result: more stable and efficient suppressor tRNAs.
Engineering and Screening
- Over 17,000 configurations were tested.
- Scientists identified a highly efficient prime-editing enzyme named PE6c.
- Combined with an additional guide RNA strategy called PE3:
- Encourages cellular DNA repair machinery to adopt edits.
Efficiency and Safety
- Editing efficiency reached 60–80% in cultured human cells.
- Much higher than traditional gene insertion methods such as:
- Homology-Directed Repair (HDR): typically, 10–20% or lower.
Safety Observations
- No disruption to:
- Overall cellular activity
- Normal protein production
- Edited system distinguished between:
- Faulty stop signals (ignored)
- Natural stop signals (respected)
Disease Models Tested
Technique evaluated in mouse models of diseases caused by premature stop codons:
- Batten disease
- Tay-Sachs disease
- Niemann-Pick C1 disease
Results in Mice
- Delivery achieved using AAV9 viral vector, a common gene-therapy carrier.
- Converted natural mouse tRNA into suppressor tRNA inside living animals.
Observations
- Restoration of missing proteins.
- Enzyme activity increased significantly.
- In Hurler syndrome mouse model:
- Protein activity restored to 1.7% of normal levels.
- Improvement seen in brain, heart, and liver.
- Improved cellular pathology.
- No signs of toxicity observed.
Scientific Significance
- Demonstrates engineered tRNA can restore protein function across multiple diseases.
- Moves gene therapy toward mutation-class treatment instead of disease-specific therapy.
- Could benefit many rare genetic disorders simultaneously.
Expert Views
- Strong laboratory evidence shows engineered tRNA restores protein function.
- Considered an important advance in genome engineering.
- However, challenges remain:
- Efficient delivery methods
- Long-term safety
- Performance across different tissues
Clinical Outlook
- Early clinical success of base editing (targeting TAG stop codons) shows feasibility.
- Viral delivery systems can reach editing sites effectively.
- PERT shows promise but requires further clinical validation before human treatment.
Why This Matters
- Reduces need for designing individual gene therapies.
- Could dramatically lower treatment cost and development time.
- Advances precision medicine and rare disease treatment.
- Represents next-generation genome editing beyond conventional CRISPR approaches.
Conclusion
The study demonstrates that prime-editing–based engineered tRNA technology (PERT) can bypass premature stop signals caused by nonsense mutations and restore normal protein production. Instead of creating separate treatments for each genetic disease, a single genome-editing platform may treat multiple disorders, marking a major step toward scalable and cost-effective gene therapy, though clinical delivery and long-term safety remain key challenges.
CARE MCQ
Q. Nonsense mutations primarily result in:
A. Increased protein production
B. Premature termination of protein synthesis
C. Duplication of chromosomes
D. Activation of silent genes
Answer: B
Explanation:
Nonsense mutations introduce premature stop codons, halting protein formation early.
